Market Access Impact (US) [PsO]
Top brand takes a big lead thanks to market barriers
In the US, market barriers are having a major impact on the brands used to treat psoriasis—affecting more than a third of all prescriptions and helping some brands stay ahead of rivals. Eliminating barriers would narrow the top brand’s sizeable lead, and send the third place brand toppling all the way down to sixth place.
Find whether barriers are holding your brand back, and what you can do about it, in Market Access Impact: Psoriasis (US).
Based on a survey of 100 dermatologists, the report covers 8 major therapies from AbbVie, Amgen, Celgene, Eli Lilly, Janssen Biotech, Novartis, and Pfizer. Handy graphs and charts reveal which of 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Reasons to Purchase
Insight into 8 Major Psoriasis Drugs
Cosentyx (secukinumab; Novartis)
Enbrel (etanercept; Amgen)
Humira (adalimumab; AbbVie)
Inflectra (infliximab-dyyb; Pfizer)
Otezla (apremilast; Celgene)
Remicade (infliximab; Janssen Biotech)
Stelara (ustekinumab; Janssen Biotech)
Taltz (ixekizumab; Eli Lilly)
Exploring Market Access Barriers
Market Access Impact: Psoriasis (US) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access:
What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?
How barriers affect your brand:
How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 100 US-based dermatologists, chosen from the largest community of validated physicians in the world.
All respondents have:
Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with psoriasis in total in the last month
We conducted the survey between February 1st and 7th, 2017.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook